Spring LM - Search Results

1

Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.

Keenan JC, Medford AJ, Dai CS, Wander SA, Spring LM, Bardia A. Keenan JC, et al. Among authors: spring lm. Expert Rev Anticancer Ther. 2024 Jun;24(6):397-405. doi: 10.1080/14737140.2024.2346188. Epub 2024 Apr 26. Expert Rev Anticancer Ther. 2024. PMID: 38642015 Review.

2

Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.

Spring L, Bardia A, Modi S. Spring L, et al. Discov Med. 2016 Jan;21(113):65-74. Discov Med. 2016. PMID: 26896604 Free PMC article.

3

Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.

Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A. Spring LM, et al. JAMA Oncol. 2016 Nov 1;2(11):1477-1486. doi: 10.1001/jamaoncol.2016.1897. JAMA Oncol. 2016. PMID: 27367583 Free PMC article. Review.

4

SWISH-ing steroids: new standard of care to prevent everolimus-induced oral mucositis?

Spring L, Bardia A. Spring L, et al. Lancet Oncol. 2017 May;18(5):564-565. doi: 10.1016/S1470-2045(17)30106-7. Epub 2017 Mar 15. Lancet Oncol. 2017. PMID: 28314690 No abstract available.

5

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.

Spring LM, Zangardi ML, Moy B, Bardia A. Spring LM, et al. Oncologist. 2017 Sep;22(9):1039-1048. doi: 10.1634/theoncologist.2017-0142. Epub 2017 Jul 13. Oncologist. 2017. PMID: 28706010 Free PMC article. Review.

6

Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.

Zangardi ML, Spring LM, Blouin GC, Bardia A. Zangardi ML, et al. Among authors: spring lm. Expert Rev Clin Pharmacol. 2017 Nov;10(11):1169-1176. doi: 10.1080/17512433.2017.1376653. Epub 2017 Sep 18. Expert Rev Clin Pharmacol. 2017. PMID: 28875723 Review.

7

Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.

Condorelli R, Spring L, O'Shaughnessy J, Lacroix L, Bailleux C, Scott V, Dubois J, Nagy RJ, Lanman RB, Iafrate AJ, Andre F, Bardia A. Condorelli R, et al. Ann Oncol. 2018 Mar 1;29(3):640-645. doi: 10.1093/annonc/mdx784. Ann Oncol. 2018. PMID: 29236940 Free article.

8

Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer.

Spring L, Bardia A. Spring L, et al. Clin Cancer Res. 2018 Jul 1;24(13):2981-2983. doi: 10.1158/1078-0432.CCR-18-0463. Epub 2018 Apr 23. Clin Cancer Res. 2018. PMID: 29685881

9

Research Biopsies: An Integrative Review of the Experiences of Patients With Cancer.

Abraham E, Post K, Spring L, Malvarosa G, Tripp E, Peppercorn JM, Bardia A, Habin K. Abraham E, et al. Clin J Oncol Nurs. 2018 Jun 1;22(3):E71-E77. doi: 10.1188/18.CJON.E71-E77. Clin J Oncol Nurs. 2018. PMID: 29781452 Review.

10

A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer.

Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, Toner M, Haber DA, Maheswaran S. Kwan TT, et al. Among authors: spring lm. Cancer Discov. 2018 Oct;8(10):1286-1299. doi: 10.1158/2159-8290.CD-18-0432. Epub 2018 Aug 13. Cancer Discov. 2018. PMID: 30104333 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters